Low rate of COVID‐19 pneumonia in kidney transplant recipients—A battle between infection and immune response?
Authors:
- Maryam Ghaffari RahbarMRMaryam Ghaffari Rahbar
- Mohsen NafarMNMohsen Nafar
- Alireza KhoshdelAKAlireza Khoshdel
- Nooshin DaliliNDNooshin Dalili
- Alireza AbrishamiAAAlireza Abrishami
- Ahmad FirouzanAFAhmad Firouzan
- Fatemeh PoorrezagholiFPFatemeh Poorrezagholi
- Fariba SamadianFSFariba Samadian
- Shadi ZiaieSZShadi Ziaie
- Somayeh FatemizadehSFSomayeh Fatemizadeh
- Shiva SamavatSSShiva Samavat
- 11 July 2020
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 22 (5) , e13406
Abstract
Background: With COVID‐19 pandemic, concerns about kidney transplant recipients are rising. However, the incidence, clinical course, outcome, and predictive factors of disease severity are obscured.Methods: We describe clinical and laboratory manifestations, radiologic findings, clinical course, and finally outcome of kidney transplant recipients with COVID‐19 pneumonia.Results: Of 2493 kidney transplant recipients under follow‐up in our clinic, 19 cases (4 cases diagnosed based on radiologic findings) were admitted. The mean age of patients was 47.6 ± 12.4 years, and the mean time from transplantation was 115.6 ± 70.3 months. Lymphopenia and eosinopenia were 84.2% and 78.9%, respectively. Nine patients did not survive the hospital course. History of acute rejection during the past 12 months, diabetes, higher N/L ratio, lower platelet count, elevated N/L x CRP, higher levels of LDH, positive D‐dimer, higher troponin, and prolonged PT were associated with mortality. Among patients with positive COVID‐19 test, history of acute rejection, low platelet count, and positive D‐dimer were associated with poor outcome. Treatment with cyclosporine was associated with better clinical outcome.Conclusions: Low rate of admission in transplant recipients specially in the very first years of transplantation might be due to protective effects of immunosuppressive agents against cytokine storm or modification of immunity function. We suggest evaluation of T‐cell number, function, and cytokine profile as a guide to manage COVID‐19 mainly in patients with higher risk of mortality.Keywords
This publication has 16 references indexed in Scilit:
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumoniaKidney International, 2020
- Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progressionInternational Journal of Infectious Diseases, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19New England Journal of Medicine, 2020
- COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposalThe Journal of Heart and Lung Transplantation, 2020
- COVID-19: immunopathology and its implications for therapyNature Reviews Immunology, 2020
- Why the immune system fails to mount an adaptive immune response to a COVID‐19 infectionTransplant International, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Reducing mortality from 2019-nCoV: host-directed therapies should be an optionThe Lancet, 2020
- Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506Virus Research, 2012